REG - Destiny Pharma PLC - Director/PDMR Shareholding

Destiny PharmaAnnouncement

05/08/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240805:nRSE2126Za&default-theme=true

RNS Number : 2126Z  Destiny Pharma PLC  05 August 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 5 August 2024 - Destiny Pharma plc (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life-threatening
infections, announces that it was notified on 2 August 2024 that on that same
day, Sir Nigel Rudd, Chairman of the Company, purchased 1,240,000 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") at a price of 2.5
pence.

Following this purchase, Sir Nigel Rudd's beneficial interest in the Company
(together with his spouse) is 3,761,716 Ordinary Shares, representing 3.93 per
cent of the total issued share capital.

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86MjE5NmNkZjQ2MzBmZGRmNjk0NDFiMTkxNDNkOWY0M2E6NjplYjEyOjY0OWNjNDIxNGUxNmMwM2YxNDQ5NmU4M2Q2YWY3YjdjN2E4MzkyNTkyYjZkMjFjYmI5N2YzN2QzYTQ5MDEzNjU6cDpGOk4)

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under Article 17 of
MAR.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.                         Details of the person discharging managerial responsibilities / person closely
                            associated
 a)                         Name                                                         Sir Nigel Rudd
 2.                         Reason for the Notification
 a)                         Position/status                                              Chairman
 b)                         Initial notification/Amendment                               Initial notification
 3.                         Details of the issuer, emission allowance market participant, auction
                            platform, auctioneer or auction monitor
 a)                         Name                                                         Destiny Pharma plc
 b)                         LEI                                                          213800O9WH9Z38EHAC95
 4.                         Details of the transaction(s): section to be repeated for (i) each type of
                            instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                            place where transactions have been conducted
 a)                         Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each
                            Identification code                                          DEST      GB00BDHSP575
 b)                         Nature of the transaction                                    Purchase of Ordinary Shares
 c)                         Price(s) and volume(s)                                        2.5 pence

                                                                                          1,240,000 Ordinary Shares
 d)                         Aggregated information:

                            Aggregated volume                                            See 4c) above

                            Price
 e)                         Date of the transaction                                      2 August 2024
 f)                         Place of the transaction                                     London Stock Exchange, AIM market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEITDIEIIS